Ensysce Biosciences, Inc. (ENSC) News
Track canonical SquawkNews coverage tagged to ENSC, Ensysce Biosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
SAN DIEGO, CA / / September 15, 2026 / Ensysce Biosciences, Inc. NASDAQ:ENSC ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an
REGULATION | Sep 15, 2026, 01:21 PM UTC
L
ENSC - Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
ENSC - Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
REGULATION | Sep 15, 2026, 01:15 PM UTC
L
Ensysce Biosciences to participate in upcoming conference events
Ensysce Biosciences said it will take part in upcoming conference and industry event participation.
EQUITY | Sep 02, 2026, 12:32 PM UTC
L
ENSC - Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
ENSC - Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
EQUITY | Sep 02, 2026, 12:32 PM UTC
L
ENSC - Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
ENSC - Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
EQUITY | Aug 20, 2026, 12:00 PM UTC
L
Ensysce Biosciences reports Q2 2026 financial results
Ensysce Biosciences (ENSC) reports second quarter 2026 financial results and recent business highlights, per TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:15 PM UTC
L
Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings
U.S. stocks traded mixed this morning, with the Nasdaq Composite falling over 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.04% to 54,373.37 while the NASDAQ fell 0.24% to 26,299.39. T
EARNINGS | Aug 06, 2026, 01:43 PM UTC
H
Small Caps Surge
Several small caps see large gains
EQUITY | Aug 04, 2026, 01:13 PM UTC
H
Premarket Gainers: RAIN +101.87%
Top premarket gainers
EQUITY | Aug 04, 2026, 09:40 AM UTC
H
Why Palantir Shares Are Trading Higher By 16%; Here Are 20 Stocks Moving Premarket
Shares of Palantir Technologies Inc (NASDAQ: PLTR ) rose sharply in pre-market trading, after the company posted upbeat financial results for the second quarter and raised its FY26 sales guidance. Palantir reported secon
EARNINGS | Aug 04, 2026, 08:42 AM UTC
H
ENSC Hits High On Patent News
ENSC rises on patent news
EQUITY | Aug 03, 2026, 08:09 PM UTC
L
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Seer (NASDAQ: SEER ) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million. Universe Pharmaceuticals (NASDAQ: UPC ) stock m
EQUITY | Jul 02, 2026, 09:05 PM UTC
M
ENSC Initiates PF614-MPAR-102 Trial
Ensysce Biosciences initiates final stage of PF614-MPAR-102 clinical trial to evaluate its MPAR overdose-protection technology
EQUITY | Jun 26, 2026, 12:04 PM UTC
M
ENSC Enrolls Patient
Ensysce Biosciences enrolls first patient in final phase of PF614-MPAR-102 clinical study
EQUITY | Jun 26, 2026, 12:00 PM UTC